Store-Operated Ca entry and iPLA2 in vascular SMC
血管 SMC 中存储操作的 Ca 进入和 iPLA2
基本信息
- 批准号:7996611
- 负责人:
- 金额:$ 42.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-06-13 至 2012-12-31
- 项目状态:已结题
- 来源:
- 关键词:ADAR1AgonistAgreementBindingBiochemicalBlood VesselsCalciumCationsCell LineCell membraneCell modelCellsComplexCouplingDataDimensionsDrosophila genusElementsEndoplasmic ReticulumEvaluationFundingGenesGoalsHealthImageIon ChannelLysophospholipidsMediatingMembrane MicrodomainsMethodsModelingModificationMolecularNitric OxidePathway interactionsPhospholipasePhospholipase A2PhysiologicalPlayProductionProtein IsoformsProteinsRNA EditingReactionRelaxationResearchRoleSTIM1 geneSignal TransductionSmooth Muscle MyocytesTestingTransducersbasecell typeconstrictionmolecular domainnovelprogramssuccess
项目摘要
DESCRIPTION (provided by applicant): Our long term goal is to define the molecular mechanism of store-operated Ca2+ entry (SOCE) in vascular smooth muscle cells (SMC) and other cell types. Recently we identified Ca2+-independent phospholipase A2¿ (iPLA2¿) as a novel determinant of SOCE, which was successfully confirmed by others. We discovered a novel plasma membrane-delimited cascade of reactions involving CIF-induced displacement of inhibitory CaM from iPLA2¿ which leads to its activation and production of lysophospholipids that in turn activate SOC channels. The importance of iPLA2¿ was fully confirmed in a recent screen of Drosophila genes, in which iPLA2¿, STIM1 and Orai1 (but not TRP) were found to play equally important roles in SOCE, but the mechanisms of their molecular and functional interactions are yet to be determined. Our preliminary studies strongly suggest that iPLA2¿ may be a key intermediate between STIM1 and Orai1. Based on the careful analysis of the most recent discoveries in the field, critical evaluation of different models, and our extensive preliminary findings, we propose a novel model of SOCE complex (SOCEplex) that brings a new dimension to SOCE mechanism, unifies conformational coupling and diffusible messenger ideas, involves STIM1, CIF, iPLA2¿ and Orai1, and offers their new structural and functional arrangement. The main hypothesis of this proposal is that iPLA2¿ is a central multifunctional element of the SOCEplex, and serves as a plasma membrane anchor for endoplasmic reticulum STIM1, acceptor of the signal from depleted stores and transducer of the signal to Orai1. Novel model of SOCE will be tested in primary vascular SMC and model cell lines using our integrative approach, which involves advanced molecular, biochemical, imaging, electrophysiological and functional methods. All approaches and methods have been established and successfully used in the PI's lab. The feasibility of our new hypothesis and success of the proposed studies are fully supported by extensive preliminary data and expertise of the PI and collaborators. Specific Aims of this proposal are: Aim 1: To establish iPLA2¿ as a molecular partner of STIM1 and Orai1, and a keystone of SOCEplex. We will assess alternative models of SOCE, establish a new role of iPLA22 as a linker between STIM1 and Orai1, identify the molecular mechanism of iPLA2¿ interaction with STIM1 and its role in SOCE, determine the mechanism of iPLA2¿ oligomerization and identify molecular domains in iPLA2¿ that are crucial for signal transduction in SOCEplex. Aim 2: To establish the roles of CIF and LysoPL in signal transduction within SOCEplex. We will confirm the role of CIF in signal transduction from depleted stores to plasma membrane, determine the role of lipid rafts, and assess LysoPL-mediated mechanism of Orai1 activation. PUBLIC HEALTH RELEVANCE: Our long term goal is to define the mechanism of store-operated Ca2+ entry (SOCE) pathway that is crucial for a wide variety of physiological functions. The goals of this proposal are to establish the role of specific plasma membrane-bound isoform of Ca2+-independent phospholipase A2 as a crucial component of SOCE machinery, and to demonstrate that it serves as a central molecular, structural and functional element of SOCE complex (SOCEplex) that transduces the signal from depleted stores to plasma membrane channels. The feasibility of our novel hypothesis is fully supported by extensive preliminary data and advanced expertise of PI's lab.
描述(由申请人提供):我们的长期目标是确定血管平滑肌细胞 (SMC) 和其他细胞类型中钙池操纵的 Ca2+ 进入 (SOCE) 的分子机制。最近,我们鉴定了不依赖 Ca2+ 的磷脂酶 A2¿ (iPLA2¿) 作为 SOCE 的一种新决定因素,这一点已被其他人成功证实,我们发现了一种新颖的质膜界定的级联反应,涉及 CIF 诱导的 iPLA2 中抑制性 CaM 的置换。这导致其激活并产生溶血磷脂,进而激活 SOC 通道 iPLA2 的重要性。最近的果蝇基因筛选得到了充分证实,其中 iPLA2¿ 、STIM1 和 Orai1(但不是 TRP)被发现在 SOCE 中发挥同样重要的作用,但它们的分子和功能相互作用的机制尚未确定,我们的初步研究强烈表明 iPLA2¿可能是 STIM1 和 Orai1 之间的关键中间体。基于对该领域最新发现的仔细分析、对不同模型的批判性评估以及我们广泛的初步发现,我们提出了一种新的 SOCE 复合体模型(SOCEplex),它带来了SOCE 机制的新维度,统一构象耦合和可扩散信使理念,涉及 STIM1、CIF、iPLA2¿和Orai1,并提供了它们新的结构和功能安排。该提案的主要假设是iPLA2¿是 SOCEplex 的核心多功能元件,充当内质网 STIM1 的质膜锚、来自耗尽存储的信号的受体以及 Orai1 信号的转导器。 SOCE 的新型模型将在原代血管 SMC 和模型细胞中进行测试。使用我们的综合方法进行生产线,其中涉及先进的分子、生化、成像、电生理和功能方法,所有方法和方法均已在 PI 实验室中建立并成功使用。我们的新假设和拟议研究的成功得到了 PI 和合作者的广泛初步数据和专业知识的充分支持。该提案的具体目标是: 目标 1:建立 iPLA2¿作为 STIM1 和 Orai1 的分子伴侣,以及 SOCEplex 的基石,我们将评估 SOCE 的替代模型,建立 iPLA22 作为 STIM1 和 Orai1 之间的链接器的新角色,确定 iPLA2 的分子机制。与 STIM1 的相互作用及其在 SOCE 中的作用,确定 iPLA2 的机制¿寡聚化并识别 iPLA2 中的分子结构域¿目标 2:确定 CIF 和 LysoPL 在 SOCEplex 信号转导中的作用,我们将确认 CIF 在从耗尽的储存到质膜的信号转导中的作用,确定脂筏的作用。并评估 LysoPL 介导的 Orai1 激活机制 公共健康相关性:我们的长期目标是确定至关重要的钙库操纵 Ca2+ 进入 (SOCE) 途径的机制。该提案的目标是确定 Ca2+ 独立磷脂酶 A2 的特定质膜结合亚型作为 SOCE 机制的重要组成部分的作用,并证明它作为中心分子, SOCE 复合体 (SOCEplex) 的结构和功能元件将信号从耗尽的储存转导到质膜通道,我们的新假设的可行性得到了 PI 实验室的大量初步数据和先进专业知识的充分支持。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Victoria M Bolotina其他文献
Victoria M Bolotina的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Victoria M Bolotina', 18)}}的其他基金
PARK14/Calcium signaling as a novel biomarker for Parkinson disease
PARK14/钙信号传导作为帕金森病的新型生物标志物
- 批准号:
9379694 - 财政年份:2017
- 资助金额:
$ 42.25万 - 项目类别:
Store-operated Ca2+ influx & iPLA2 in vascular SMC
商店操作的 Ca2 流入
- 批准号:
7067126 - 财政年份:2003
- 资助金额:
$ 42.25万 - 项目类别:
Store-Operated Ca entry and iPLA2 in vascular SMC
血管 SMC 中存储操作的 Ca 进入和 iPLA2
- 批准号:
8207925 - 财政年份:2003
- 资助金额:
$ 42.25万 - 项目类别:
Store-operated Ca2+ influx & iPLA2 in vascular SMC
商店操作的 Ca2 流入
- 批准号:
6679543 - 财政年份:2003
- 资助金额:
$ 42.25万 - 项目类别:
Store-operated Ca2+ influx & iPLA2 in vascular SMC
商店操作的 Ca2 流入
- 批准号:
6759324 - 财政年份:2003
- 资助金额:
$ 42.25万 - 项目类别:
Store-Operated Ca entry and iPLA2 in vascular SMC
血管 SMC 中存储操作的 Ca 进入和 iPLA2
- 批准号:
7584587 - 财政年份:2003
- 资助金额:
$ 42.25万 - 项目类别:
Store-Operated Ca entry and iPLA2 in vascular SMC
血管 SMC 中存储操作的 Ca 进入和 iPLA2
- 批准号:
7741705 - 财政年份:2003
- 资助金额:
$ 42.25万 - 项目类别:
相似国自然基金
α7nAChR激动剂通过PGC-1α和HO-1调控肾小管上皮细胞线粒体的质和量进而改善脓毒症急性肾损伤的机制研究
- 批准号:82372172
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
基于纳米铝乳剂和模式识别受体激动剂的复合型佐剂研究
- 批准号:82341043
- 批准年份:2023
- 资助金额:110 万元
- 项目类别:专项基金项目
新型IL2Rβγ激动剂逐级控释联合放疗对抗三阴性乳腺癌的作用及机制研究
- 批准号:82303819
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
卡瓦胡椒中选择性大麻素2型受体激动剂的发现及其抗骨质疏松作用研究
- 批准号:82360684
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
脂质纳米粒体内介导嵌合抗原受体-M1型巨噬细胞协同TLR激动剂治疗实体瘤的研究
- 批准号:82304418
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Gene-environment interaction in islet serotonin metabolism and impacts on maternal glucose homeostasis
胰岛血清素代谢中的基因-环境相互作用及其对母体葡萄糖稳态的影响
- 批准号:
10634224 - 财政年份:2023
- 资助金额:
$ 42.25万 - 项目类别:
Implementing a patient navigation intervention across a health system to address treatment entry inequities
在整个卫生系统中实施患者导航干预,以解决治疗进入不平等问题
- 批准号:
10812628 - 财政年份:2023
- 资助金额:
$ 42.25万 - 项目类别:
Targeting visceral pain through intestinal neuropod cell GUCY2C signaling
通过肠道神经足细胞 GUCY2C 信号传导治疗内脏疼痛
- 批准号:
10837293 - 财政年份:2023
- 资助金额:
$ 42.25万 - 项目类别:
Establishing sex-specific mechanisms for estrogen receptor beta in heroin extinction memory recall
建立海洛因灭绝记忆回忆中雌激素受体β的性别特异性机制
- 批准号:
10678227 - 财政年份:2023
- 资助金额:
$ 42.25万 - 项目类别:
VesiVax Vaccine Formulation Against Neisseria gonorrhoeae
针对淋病奈瑟氏菌的 VesiVax 疫苗配方
- 批准号:
10385208 - 财政年份:2022
- 资助金额:
$ 42.25万 - 项目类别: